{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T17:05:40Z","timestamp":1790960740010,"version":"4.1.0"},"reference-count":70,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100013101","name":"National Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013101","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005930","name":"Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005930","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005930","name":"Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005930","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaacap.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Child & Adolescent Psychiatry"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1016\/j.jaac.2019.01.015","type":"journal-article","created":{"date-parts":[[2019,3,8]],"date-time":"2019-03-08T21:20:59Z","timestamp":1552080059000},"page":"1062-1078","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"title":["Cardiometabolic Adverse Effects and Its Predictors in Children and Adolescents With First-Episode Psychosis During Treatment With Quetiapine-Extended Release Versus Aripiprazole: 12-Week Results From the Tolerance and Effect of Antipsychotics in Children and Adolescents With Psychosis (TEA) Trial"],"prefix":"10.1016","volume":"58","author":[{"given":"Karsten Gjessing","family":"Jensen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph U.","family":"Correll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ditte","family":"Rud\u00e5","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dea Gowers","family":"Klauber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie Stentebjerg","family":"Decara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birgitte","family":"Fagerlund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens Richardt M\u00f8llegaard","family":"Jepsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Eriksson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders","family":"Fink-Jensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne Katrine","family":"Pagsberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaac.2019.01.015_bib1","doi-asserted-by":"crossref","first-page":"e19590","DOI":"10.1371\/journal.pone.0019590","article-title":"Life expectancy at birth for people with serious mental illness and other major disorders from a secondary mental health care case register in London","volume":"6","author":"Chang","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.jaac.2019.01.015_bib2","doi-asserted-by":"crossref","first-page":"e67133","DOI":"10.1371\/journal.pone.0067133","article-title":"Life expectancy and death by diseases of the circulatory system in patients with bipolar disorder or schizophrenia in the Nordic countries","volume":"8","author":"Laursen","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.jaac.2019.01.015_bib3","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S0920-9964(99)00191-7","article-title":"Mortality and causes of death in schizophrenia in Stockholm County, Sweden","volume":"45","author":"Osby","year":"2000","journal-title":"Schizophr Res"},{"key":"10.1016\/j.jaac.2019.01.015_bib4","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1080\/08039480701414932","article-title":"Mortality among persons with schizophrenia in Sweden: an epidemiological study","volume":"61","author":"Fors","year":"2007","journal-title":"Nordic J Psychiatry"},{"key":"10.1016\/j.jaac.2019.01.015_bib5","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1097\/YCO.0b013e32835035ca","article-title":"Life expectancy and cardiovascular mortality in persons with schizophrenia","volume":"25","author":"Laursen","year":"2012","journal-title":"Curr Opin Psychiatry"},{"key":"10.1016\/j.jaac.2019.01.015_bib6","doi-asserted-by":"crossref","first-page":"e55176","DOI":"10.1371\/journal.pone.0055176","article-title":"Excess mortality, causes of death and life expectancy in 270,770 patients with recent onset of mental disorders in Denmark, Finland and Sweden","volume":"8","author":"Nordentoft","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.jaac.2019.01.015_bib7","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.molmed.2010.10.010","article-title":"Antipsychotic drugs and obesity","volume":"17","author":"Correll","year":"2011","journal-title":"Trends Mol Med"},{"key":"10.1016\/j.jaac.2019.01.015_bib8","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1176\/appi.ajp.160.2.284","article-title":"Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia","volume":"160","author":"Ryan","year":"2003","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.jaac.2019.01.015_bib9","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1080\/09540260500071798","article-title":"The metabolic syndrome and schizophrenia: a review","volume":"17","author":"Meyer","year":"2005","journal-title":"Int Rev Psychiatry"},{"key":"10.1016\/j.jaac.2019.01.015_bib10","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1038\/nrendo.2011.156","article-title":"Metabolic and cardiovascular adverse effects associated with antipsychotic drugs","volume":"8","author":"De Hert","year":"2012","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.jaac.2019.01.015_bib11","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.chc.2013.06.002","article-title":"Psychopharmacologic treatment of psychosis in children and adolescents: efficacy and management","volume":"22","author":"Kranzler","year":"2013","journal-title":"Child Adolesc Psychiatr Clin North Am"},{"key":"10.1016\/j.jaac.2019.01.015_bib12","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1186\/1471-244X-12-150","article-title":"A\u00a0systematic review of the long-term outcome of early onset schizophrenia","volume":"12","author":"Clemmensen","year":"2012","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.jaac.2019.01.015_bib13","first-page":"121","article-title":"Schizophrenia and related disorders in children and adolescents","author":"Remschmidt","year":"2005","journal-title":"J\u00a0Neural Transm Suppl"},{"key":"10.1016\/j.jaac.2019.01.015_bib14","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.eurpsy.2010.09.011","article-title":"Metabolic and endocrine adverse effects of second-generation antipsychotics in children and adolescents: a systematic review of randomized, placebo controlled trials and guidelines for clinical practice","volume":"26","author":"De Hert","year":"2011","journal-title":"Eur Psychiatry"},{"key":"10.1016\/j.jaac.2019.01.015_bib15","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1001\/archgenpsychiatry.2011.2","article-title":"Systematic review of early cardiometabolic outcomes of the first treated episode of psychosis","volume":"68","author":"Foley","year":"2011","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.jaac.2019.01.015_bib16","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s11892-010-0112-8","article-title":"Metabolic syndrome associated with schizophrenia and atypical antipsychotics","volume":"10","author":"Hasnain","year":"2010","journal-title":"Curr Diabetes Rep"},{"key":"10.1016\/j.jaac.2019.01.015_bib17","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1586\/ern.10.85","article-title":"Management of antipsychotic-related weight gain","volume":"10","author":"Maayan","year":"2010","journal-title":"Expert Rev Neurother"},{"key":"10.1016\/j.jaac.2019.01.015_bib18","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1097\/YCO.0b013e32833f46c9","article-title":"Cardiovascular aspects of antipsychotics","volume":"23","author":"Raedler","year":"2010","journal-title":"Curr Opin Psychiatry"},{"key":"10.1016\/j.jaac.2019.01.015_bib19","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/j.1600-0447.2008.01334.x","article-title":"Which comes first: atypical antipsychotic treatment or cardiometabolic risk?","volume":"119","author":"Stahl","year":"2009","journal-title":"Acta PsychiatrScand"},{"key":"10.1016\/j.jaac.2019.01.015_bib20","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1517\/14740338.2015.979150","article-title":"Do antipsychotics increase diabetes risk in children and adolescents?","volume":"14","author":"Galling","year":"2015","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.jaac.2019.01.015_bib21","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1001\/jamapsychiatry.2015.2923","article-title":"Type 2 diabetes mellitus in youth exposed to antipsychotics: a systematic review and meta-analysis","volume":"73","author":"Galling","year":"2016","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.jaac.2019.01.015_bib22","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1001\/archgenpsychiatry.2012.647","article-title":"National trends in the office-based treatment of children, adolescents, and adults with antipsychotics","volume":"69","author":"Olfson","year":"2012","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.jaac.2019.01.015_bib23","first-page":"124","article-title":"First do no harm: promoting an evidence-based approach to atypical antipsychotic use in children and adolescents","volume":"19","author":"Panagiotopoulos","year":"2010","journal-title":"J\u00a0Can Acad Child AdolescPsychiatry"},{"key":"10.1016\/j.jaac.2019.01.015_bib24","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1111\/acps.12155","article-title":"Nationwide time trends in dispensed prescriptions of psychotropic medication for children and adolescents in Denmark","volume":"129","author":"Steinhausen","year":"2014","journal-title":"Acta Psychiatr Scand"},{"key":"10.1016\/j.jaac.2019.01.015_bib25","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1016\/j.euroneuro.2017.07.001","article-title":"International trends in antipsychotic use: a study in 16 countries, 2005-2014","volume":"27","author":"Halfdanarson","year":"2017","journal-title":"Eur Neuropsychopharmacol"},{"key":"10.1016\/j.jaac.2019.01.015_bib26","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1097\/JCP.0b013e3182549259","article-title":"Adverse effects of second-generation antipsychotics in children and adolescents: a Bayesian meta-analysis","volume":"32","author":"Cohen","year":"2012","journal-title":"J\u00a0Clin Psychopharmacol"},{"key":"10.1016\/j.jaac.2019.01.015_bib27","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1001\/jama.2009.1549","article-title":"Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents","volume":"302","author":"Correll","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.jaac.2019.01.015_bib28","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1089\/cap.2012.0092","article-title":"Safety, tolerability, and efficacy of quetiapine in youth with schizophrenia or bipolar I disorder: a 26-week, open-label, continuation study","volume":"23","author":"Findling","year":"2013","journal-title":"J\u00a0Child Adolesc Psychopharmacol"},{"key":"10.1016\/j.jaac.2019.01.015_bib29","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1089\/104454601317261591","article-title":"A\u00a0study of quetiapine: efficacy and tolerability in psychotic adolescents","volume":"11","author":"Shaw","year":"2001","journal-title":"J\u00a0Child Adolesc Psychopharmacol"},{"key":"10.1016\/j.jaac.2019.01.015_bib30","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1007\/s00787-009-0749-5","article-title":"Olanzapine compared to quetiapine in adolescents with a first psychotic episode","volume":"18","author":"Arango","year":"2009","journal-title":"Eur Child Adolesc Psychiatry"},{"key":"10.1016\/j.jaac.2019.01.015_bib31","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1089\/cap.2007.0048","article-title":"A\u00a0prospective 12-week study of quetiapine in adolescents with schizophrenia spectrum disorders","volume":"17","author":"Schimmelmann","year":"2007","journal-title":"J\u00a0Child Adolesc Psychopharmacol"},{"key":"10.1016\/j.jaac.2019.01.015_bib32","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s40272-015-0119-3","article-title":"Use of quetiapine in children and adolescents","volume":"17","author":"Masi","year":"2015","journal-title":"Paediatr Drugs"},{"key":"10.1016\/j.jaac.2019.01.015_bib33","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1016\/j.jaac.2014.08.009","article-title":"Second-generation antipsychotic use in children and adolescents: a six-month prospective cohort study in drug-naive patients","volume":"53","author":"Arango","year":"2014","journal-title":"J\u00a0Am Acad Child Adolesc Psychiatry"},{"key":"10.1016\/j.jaac.2019.01.015_bib34","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/j.jaac.2014.04.023","article-title":"Risk of diabetes in children and adolescents exposed to antipsychotics: a nationwide 12-year case-control study","volume":"53","author":"Nielsen","year":"2014","journal-title":"J\u00a0Am Acad Child Adolesc Psychiatry"},{"key":"10.1016\/j.jaac.2019.01.015_bib35","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1001\/jamapsychiatry.2016.3803","article-title":"Impaired glucose homeostasis in first-episode schizophrenia: a systematic review and meta-analysis","volume":"74","author":"Pillinger","year":"2017","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.jaac.2019.01.015_bib36","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1089\/cap.2015.0097","article-title":"Clinical characteristics and predictors of outcome of schizophrenia-spectrum psychosis in children and adolescents: a systematic review","volume":"26","author":"Stentebjerg-Olesen","year":"2016","journal-title":"J\u00a0Child Adolesc Psychopharmacol"},{"key":"10.1016\/j.jaac.2019.01.015_bib37","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1097\/chi.0b013e318054678d","article-title":"Neurocognitive deficits in adolescents with schizophrenia: longitudinal stability and predictive utility for short-term functional outcome","volume":"46","author":"Cervellione","year":"2007","journal-title":"J\u00a0Am Acad Child Adolesc Psychiatry"},{"key":"10.1016\/j.jaac.2019.01.015_bib38","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s00787-005-0436-0","article-title":"Stability and prediction of schizophrenia from adolescence to adulthood","volume":"14","author":"Helgeland","year":"2005","journal-title":"Eur Child Adolesc Psychiatry"},{"key":"10.1016\/j.jaac.2019.01.015_bib39","doi-asserted-by":"crossref","first-page":"f150","DOI":"10.1136\/bmj.f150","article-title":"Recognition and management of psychosis and schizophrenia in children and young people: summary of NICE guidance","volume":"346","author":"Kendall","year":"2013","journal-title":"BMJ"},{"key":"10.1016\/j.jaac.2019.01.015_bib40","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.2165\/11596300-000000000-00000","article-title":"Atypical antipsychotic-induced weight gain: insights into mechanisms of action","volume":"25","author":"Roerig","year":"2011","journal-title":"CNS Drugs"},{"key":"10.1016\/j.jaac.2019.01.015_bib41","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.jchemneu.2016.07.010","article-title":"Crosstalk between insulin and dopamine signaling: a basis for the metabolic effects of antipsychotic drugs","volume":"83-84","author":"Nash","year":"2017","journal-title":"J\u00a0Chem Neuroanat"},{"key":"10.1016\/j.jaac.2019.01.015_bib42","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.schres.2012.11.016","article-title":"Insulin secretion in patients receiving clozapine, olanzapine, quetiapine and risperidone","volume":"143","author":"Manu","year":"2013","journal-title":"Schizophr Res"},{"key":"10.1016\/j.jaac.2019.01.015_bib43","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.15m10479","article-title":"Pretreatment cardiometabolic status in youth with early-onset psychosis: baseline results from the TEA trial","author":"Jensen","year":"2017","journal-title":"J\u00a0Clin Psychiatry"},{"key":"10.1016\/j.jaac.2019.01.015_bib44","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/S2215-0366(17)30166-9","article-title":"Quetiapine extended release versus aripiprazole in children and adolescents with first-episode psychosis: the multicentre, double-blind, randomised tolerability and efficacy of antipsychotics (TEA) trial","volume":"4","author":"Pagsberg","year":"2017","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.jaac.2019.01.015_bib45","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1186\/1471-244X-14-199","article-title":"Quetiapine versus aripiprazole in children and adolescents with psychosis\u2500protocol for the randomised, blinded clinical Tolerability and Efficacy of Antipsychotics (TEA) trial","volume":"14","author":"Pagsberg","year":"2014","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.jaac.2019.01.015_bib46","series-title":"The ICD-10 Classification of Mental and Behavioural Disorders: Clinical Descriptions and Diagnostic Guidelines","year":"1992"},{"key":"10.1016\/j.jaac.2019.01.015_bib47","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1097\/00004583-199707000-00021","article-title":"Schedule for Affective Disorders and Schizophrenia for School-Age Children\u2212Present and Lifetime Version (K-SADS-PL): initial reliability and validity data","volume":"36","author":"Kaufman","year":"1997","journal-title":"J\u00a0Am Acad Child Adolesc Psychiatry"},{"key":"10.1016\/j.jaac.2019.01.015_bib48","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","article-title":"The Positive and Negative Syndrome Scale (PANSS) for schizophrenia","volume":"13","author":"Kay","year":"1987","journal-title":"Schizophr Bull"},{"key":"10.1016\/j.jaac.2019.01.015_bib49","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.dsx.2012.09.004","article-title":"Use of HbA(1C) testing to diagnose pre-diabetes in high risk African American children: a comparison with fasting glucose and HOMA-IR","volume":"6","author":"Sharma","year":"2012","journal-title":"Diabetes Metab Synd"},{"key":"10.1016\/j.jaac.2019.01.015_bib50","doi-asserted-by":"crossref","first-page":"36","DOI":"10.4239\/wjd.v1.i2.36","article-title":"Surrogate markers of insulin resistance: a review","volume":"1","author":"Singh","year":"2010","journal-title":"World J Diabetes"},{"key":"10.1016\/j.jaac.2019.01.015_bib51","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.2337\/dc06-0709","article-title":"Prevalence and determinants of insulin resistance among U.S. adolescents: a population-based study","volume":"29","author":"Lee","year":"2006","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jaac.2019.01.015_bib52","series-title":"Folkesundhedsrapporten Danmark 2007","author":"Kj\u00f8ller","year":"2007"},{"key":"10.1016\/j.jaac.2019.01.015_bib53","series-title":"Statistics Denmark","article-title":"Dansk Uddannelses Nomenklatur","author":"DUN","year":"2006"},{"key":"10.1016\/j.jaac.2019.01.015_bib54","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/0920-9964(92)90004-O","article-title":"IRAOS: an instrument for the assessment of onset and early course of schizophrenia","volume":"6","author":"Hafner","year":"1992","journal-title":"Schizophr Res"},{"key":"10.1016\/j.jaac.2019.01.015_bib55","author":"World Health Organization"},{"key":"10.1016\/j.jaac.2019.01.015_bib56","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1111\/j.1399-5448.2007.00271.x","article-title":"The metabolic syndrome in children and adolescents\u2500an IDF consensus report","volume":"8","author":"Zimmet","year":"2007","journal-title":"Pediatr Diabetes"},{"key":"10.1016\/j.jaac.2019.01.015_bib57","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1111\/j.1651-2227.2011.02370.x","article-title":"Waist circumference and waist-to-height ratio in Norwegian children 4-18 years of age: reference values and cut-off levels","volume":"100","author":"Brannsether","year":"2011","journal-title":"Acta Paediatr"},{"key":"10.1016\/j.jaac.2019.01.015_bib58","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1111\/apa.12468","article-title":"The 2014 Danish references from birth to 20 years for height, weight and body mass index","volume":"103","author":"Tinggaard","year":"2014","journal-title":"Acta Paediatr"},{"key":"10.1016\/j.jaac.2019.01.015_bib59","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/S0140-6736(13)60733-3","article-title":"Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis","volume":"382","author":"Leucht","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.jaac.2019.01.015_bib60","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.jaac.2016.12.013","article-title":"Acute antipsychotic treatment of children and adolescents with schizophrenia-spectrum disorders: a systematic review and network meta-analysis","volume":"56","author":"Pagsberg","year":"2017","journal-title":"J\u00a0Am Acad Child Adolesc Psychiatry"},{"key":"10.1016\/j.jaac.2019.01.015_bib61","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.euroneuro.2018.03.008","article-title":"Efficacy, acceptability, and tolerability of antipsychotics in children and adolescents with schizophrenia: a network meta-analysis","volume":"28","author":"Krause","year":"2018","journal-title":"Eur Neuropsychopharmacol"},{"key":"10.1016\/j.jaac.2019.01.015_bib62","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1097\/FPC.0000000000000249","article-title":"Prediction of early weight gain during psychotropic treatment using a combinatorial model with clinical and genetic markers","volume":"26","author":"Vandenberghe","year":"2016","journal-title":"Pharmacogenet Genomics"},{"key":"10.1016\/j.jaac.2019.01.015_bib63","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.4088\/JCP.08r04392","article-title":"Are weight gain and metabolic side effects of atypical antipsychotics dose dependent? A literature review","volume":"70","author":"Simon","year":"2009","journal-title":"J\u00a0Clin Psychiatry"},{"key":"10.1016\/j.jaac.2019.01.015_bib64","doi-asserted-by":"crossref","first-page":"e1417","DOI":"10.4088\/JCP.14m09358","article-title":"Importance of early weight changes to predict long-term weight gain during psychotropic drug treatment","volume":"76","author":"Vandenberghe","year":"2015","journal-title":"J\u00a0Clin Psychiatry"},{"key":"10.1016\/j.jaac.2019.01.015_bib65","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1176\/appi.ajp.2013.13060771","article-title":"Metformin for antipsychotic-related weight gain and metabolic abnormalities: when, for whom, and for how long?","volume":"170","author":"Correll","year":"2013","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.jaac.2019.01.015_bib66","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1093\/schbul\/sbw058","article-title":"Pharmacogenetic associations of antipsychotic drug-related weight gain: a systematic review and meta-analysis","volume":"42","author":"Zhang","year":"2016","journal-title":"Schizophr Bull"},{"key":"10.1016\/j.jaac.2019.01.015_bib67","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1056\/NEJMoa072515","article-title":"Childhood body-mass index and the risk of coronary heart disease in adulthood","volume":"357","author":"Baker","year":"2007","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaac.2019.01.015_bib68","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1056\/NEJMoa1006992","article-title":"Adolescent BMI trajectory and risk of diabetes versus coronary disease","volume":"364","author":"Tirosh","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaac.2019.01.015_bib69","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1111\/j.1467-789X.2012.01015.x","article-title":"The impact of childhood obesity on morbidity and mortality in adulthood: a systematic review","volume":"13","author":"Park","year":"2012","journal-title":"Obes Rev"},{"key":"10.1016\/j.jaac.2019.01.015_bib70","doi-asserted-by":"crossref","first-page":"390130","DOI":"10.1155\/2013\/390130","article-title":"Youth, caregiver, and prescriber experiences of antipsychotic-related weight gain","volume":"2013","author":"Murphy","year":"2013","journal-title":"ISRN Obesity"}],"container-title":["Journal of the American Academy of Child & Adolescent Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0890856719301819?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0890856719301819?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T14:26:49Z","timestamp":1760192809000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0890856719301819"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":70,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2019,11]]}},"alternative-id":["S0890856719301819"],"URL":"https:\/\/doi.org\/10.1016\/j.jaac.2019.01.015","relation":{},"ISSN":["0890-8567"],"issn-type":[{"value":"0890-8567","type":"print"}],"subject":[],"published":{"date-parts":[[2019,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cardiometabolic Adverse Effects and Its Predictors in Children and Adolescents With First-Episode Psychosis During Treatment With Quetiapine-Extended Release Versus Aripiprazole: 12-Week Results From the Tolerance and Effect of Antipsychotics in Children and Adolescents With Psychosis (TEA) Trial","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Child & Adolescent Psychiatry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaac.2019.01.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a92019 American Academy of Child and Adolescent Psychiatry","name":"copyright","label":"Copyright"}]}}